Geode Capital Management, LLC Aptinyx Inc. Transaction History

Geode Capital Management, LLC

  • $1.21 Trillion
  • Q3 2024

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2022

Feb 13, 2023
SELL
$0.23 - $0.34 $191 - $282
-832 Reduced 0.22%
377,582 $110,000
Q1 2022

May 13, 2022
BUY
$2.27 - $3.62 $18,886 - $30,118
8,320 Added 2.25%
378,414 $858,000
Q4 2021

Feb 11, 2022
SELL
$2.11 - $3.0 $71 - $102
-34 Reduced 0.01%
370,094 $988,000
Q3 2021

Nov 12, 2021
SELL
$2.21 - $2.89 $8 - $11
-4 Reduced -0.0%
370,128 $866,000
Q2 2021

Aug 13, 2021
SELL
$2.39 - $3.5 $547,651 - $802,000
-229,143 Reduced 38.24%
370,132 $1.05 Million
Q1 2021

May 12, 2021
BUY
$2.86 - $4.33 $304,758 - $461,400
106,559 Added 21.63%
599,275 $1.8 Million
Q4 2020

Feb 12, 2021
BUY
$2.93 - $4.3 $337,538 - $495,364
115,201 Added 30.52%
492,716 $1.7 Million
Q3 2020

Nov 13, 2020
BUY
$3.05 - $4.99 $6,151 - $10,064
2,017 Added 0.54%
377,515 $1.28 Million
Q2 2020

Aug 13, 2020
BUY
$1.99 - $4.4 $335,619 - $742,073
168,653 Added 81.54%
375,498 $1.57 Million
Q1 2020

May 14, 2020
BUY
$1.81 - $5.03 $232,735 - $646,772
128,583 Added 164.3%
206,845 $446,000
Q4 2019

Feb 13, 2020
SELL
$2.84 - $4.25 $3,535 - $5,291
-1,245 Reduced 1.57%
78,262 $267,000
Q3 2019

Nov 12, 2019
SELL
$3.0 - $4.08 $6,657 - $9,053
-2,219 Reduced 2.72%
79,507 $277,000
Q2 2019

Aug 14, 2019
SELL
$2.95 - $4.38 $119,873 - $177,981
-40,635 Reduced 33.21%
81,726 $272,000
Q1 2019

May 14, 2019
BUY
$3.99 - $19.33 $59,439 - $287,959
14,897 Added 13.86%
122,361 $495,000
Q4 2018

Feb 13, 2019
BUY
$16.15 - $28.93 $289,311 - $518,252
17,914 Added 20.0%
107,464 $1.78 Million
Q3 2018

Nov 13, 2018
BUY
$20.21 - $31.85 $1.81 Million - $2.85 Million
89,550 New
89,550 $2.59 Million

About Aptinyx Inc.

APTX Quotes by TradingView
  • Ticker APTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 67,715,696
  • Description
  • Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. The company is developing NYX-2925, which is in Phase II clinical development for the treatment of painful diabetic pe...
More about APTX
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email